Trial Profile
A randomised, open label, two-period, cross-over, multi-centre study to compare correct inhaler handling of fluticasone/ formoterol breath-actuated inhaler (K-haler) with that of Symbicort Turbohaler in subjects with persistent asthma, ACOS or COPD.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Mar 2019
Price :
$35
*
At a glance
- Drugs Formoterol/fluticasone propionate (Primary) ; Budesonide/formoterol
- Indications Asthma; Chronic obstructive pulmonary disease
- Focus Registrational; Therapeutic Use
- Acronyms Preffer
- Sponsors Mundipharma Research
- 19 Sep 2018 Primary endpoint [Critical Device Handling Success (OC)] has been met.
- 19 Sep 2018 Results presented at the 28th Annual Congress of the European Respiratory Society
- 16 Sep 2017 Status changed from recruiting to completed.